二肽基肽酶Ⅳ抑制剂潜在心血管获益的机制探讨被引量：3

导出

摘要二肽基肽酶Ⅳ（DPP-4）抑制剂作为一类新型降糖药物,近些年越来越受到临床医生的关注.它的主要作用机制是阻断内源性的胰高糖素样肽（GLP-1和2）以及葡萄糖依赖性促胰岛素释放多肽（GIP）的降解,从而增加葡萄糖调节的胰岛素分泌,抑制胰高糖素的分泌[1-2].DPP-4抑制剂的平均降低糖化血红蛋白的作用为0.5％～ 1.0％,这类药物的降糖疗效是肯定的,并且相对的安全性和患者耐受性较好,我国已经陆续上市的四种DPP-4抑制剂.由于一些药物如罗格列酮和磺脲类可能在降低血糖的同时增加心血管事件的风险,因此人们普遍担忧新研发的降糖药物的心血管安全性[3-4].

作者李霖苏娴

机构地区济南军区总医院内分泌科北京大学医学部临床研究所

出处《中华糖尿病杂志》 CAS CSCD 2014年第6期432-434,共3页 CHINESE JOURNAL OF DIABETES MELLITUS

关键词二肽基肽酶Ⅳ抑制剂心血管事件葡萄糖依赖性胰高糖素样肽心血管安全性胰岛素分泌降糖药物糖化血红蛋白

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献23

1Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis [ J]. JAMA, 2007,298 : 194-206.
2Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics ( glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase4 inhibitors [ J ]. Pharmacol Ther, 2009, 124 : 113-138.
3Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial Infarction and death from cardiovascular causes[ J]. N Engl J Med, 2007,356:2457-2471.
4Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP [ J]. Am Heart J, 1999, 138 : S346-352.
5Guidance for industry diabetes mellitus-evaluatlng carmovascular risk in new antidiabetic therapies to treat type 2 diabetes [ DB/ OL]. Silver Spring: Food and Drug Administration, 2008 [2013- 09-03 ]. http ://www. fda. gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UC51071627. pdf.
6Rizzo M, Rizvi AA, Spinas GA, et al. Glucose lowering and anti- atherogenic effects of incretinbased therapies: GLP-1 analogues and DPP-4-inhibitors[ J]. Expert Opin Investig Drugs,2009,18: 1495 -1503.
7Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidylpeptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients [ J ]. J Clin Endocrinol Metab, 2009,94 : 846-852.
8Shah Z, Pineda C, Kampfrath T, et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways[ J]. Vascular Pharmacology ,2009,55 : 1-3.
9Ogawa S, Ishiki M, Nako K, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes [ J]. Tohoku J Exp Med, 2011,223 : 133-135.
10Anagnostis P, Athyros VG, Adamidou F, et al. Glueagon-like peptide-l-based therapies and cardiovascular disease: looking beyond glycaemic control[ J ]. Diabetes Obes Metab, 2011, 13 : 302-312.